Originally developed for human viral infections, including COVID-19, molnupiravir has emerged as a promising option for both first- and second-line therapy of Feline Infectious Peritonitis (FIP).
Objective: To review relevant studies for both primary and secondary antibiotic prophylaxis of spontaneous bacterial peritonitis (SBP) in patients with cirrhosis without gastrointestinal bleeding.